BEAM Beam Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BEAM

Price (delayed)

$24.37

Market cap

$2.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.68

Enterprise value

$2.54B

?
Relative Growth: Rel. Growth: 66
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 47

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene ...

Highlights
Beam Therapeutics's revenue has soared by 159% YoY but it has decreased by 4.9% from the previous quarter
BEAM's gross profit has surged by 159% year-on-year but it is down by 4.9% since the previous quarter
The debt has soared by 60% YoY
BEAM's equity is down by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.beamtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of BEAM

BEAM stock price

How has the Beam Therapeutics stock price performed over time
Intraday
-6.02%
1 week
5.5%
1 month
-18.11%
1 year
2.7%
YTD
-12.09%
QTD
-28.99%

Financial performance

How have Beam Therapeutics's revenue and profit performed over time
Revenue
$156.04M
Gross profit
$156.04M
Operating income
-$378.02M
Net income
-$85.43M
Gross margin
100%
Net margin
-54.7%
Beam Therapeutics's revenue has soared by 159% YoY but it has decreased by 4.9% from the previous quarter
BEAM's gross profit has surged by 159% year-on-year but it is down by 4.9% since the previous quarter
The net margin has soared by 92% YoY but it has contracted by 38% from the previous quarter
The net income has surged by 79% year-on-year but it has declined by 32% since the previous quarter

Price vs fundamentals

How does BEAM's price correlate with its fundamentals

Growth

What is Beam Therapeutics's growth rate over time

Valuation

What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
2.35
P/S
16.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.27
The EPS has surged by 85% year-on-year but it has declined by 36% since the previous quarter
The price to book (P/B) is 22% lower than the 5-year quarterly average of 3.2 and 3.8% lower than the last 4 quarters average of 2.6
BEAM's equity is down by 8% since the previous quarter
Beam Therapeutics's revenue has soared by 159% YoY but it has decreased by 4.9% from the previous quarter
BEAM's price to sales (P/S) is 96% lower than its 5-year quarterly average of 398.6 and 32% lower than its last 4 quarters average of 25.6

Efficiency

How efficient is Beam Therapeutics business performance
The return on sales has surged by 92% year-on-year but it has declined by 38% since the previous quarter
BEAM's ROIC has soared by 84% YoY but it is down by 25% QoQ
The ROE has soared by 82% YoY but it has decreased by 31% QoQ
The company's return on assets has surged by 81% YoY but it fell by 30% QoQ

Dividends

What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BEAM.

Financial health

How did Beam Therapeutics financials performed over time
BEAM's current ratio has soared by 116% YoY but it is down by 14% QoQ
BEAM's quick ratio has surged by 116% year-on-year but it is down by 12% since the previous quarter
The debt is 77% less than the equity
The debt has soared by 60% YoY
The company's debt to equity has surged by 53% YoY and by 4.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.